NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

IDEXX Laboratories, Inc. (IDXX) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

IDXX

$535.38

+$6.09 (+1.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IDXX with… →

IDXX Key Statistics

As of Sep 4, 2026
Trading
Open
$522.05
Previous Close
$529.29
Day's Range
522.05–536.09
52-Week Range
518.55–769.98
Volume
407.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.54
Valuation
Market Cap
$42.18B
P/E Ratio
37.18
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
31.98
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.98
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.26
EPS (ttm)Profit attributable to each share over the last twelve months.
14.40
Financials (FY)
Revenue (FY)
$4.30B+10.42%
Net Income (FY)
$1.06B+19.33%
Profit marginThe share of revenue left as profit after all costs and taxes.
25.03%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
78.78M
1-Year Return
−16.40%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
621.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IDXX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−20.86%
2025+63.63%
2024−25.51%
2023+36.06%
2022−38.04%
2021+31.73%
2020+91.43%
2019+40.38%
2018+18.95%
2017+33.35%
2016 (partial year)+7.96%

As of September 4, 2026.

IDXX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.30B$1.06B24.6%
2024$3.90B$887.87M22.8%
2023$3.66B$845.04M23.1%
2022$3.37B$679.09M20.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.30B$2.66B$1.36B$1.06B24.6%
2024$3.90B$2.38B$1.13B$887.87M22.8%
2023$3.66B$2.19B$1.10B$845.04M23.1%
2022$3.37B$2.00B$898.77M$679.09M20.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IDXX Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricIDXXDiagnostics & Research medianvs median
P/E37.1833.0812% above
P/S ratio9.264.9986% above
Profit margin25.03%0.00%25.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IDEXX Laboratories, Inc. (IDXX) carries a market capitalisation of $42.18B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 11,000.

Over the past 52 weeks the price has ranged from $518.55 to $769.98. The most recent close on file for IDXX is $535.38, dated September 4, 2026. That is +$6.09 (+1.15%) against the previous close. The latest close sits 3.25% above that 52-week low.

Financial Health

In fiscal 2025, IDEXX Laboratories, Inc. reported revenue of $4.30B. That is +10.42% against the prior fiscal year, when revenue was $3.90B. Net income for the same year was $1.06B. That is +19.33% against the prior fiscal year. The reported profit margin is 25.03%. That is 25 percentage points above the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to 14.4.

Across the 4 fiscal years on file, revenue moves from $3.37B in 2022 to $4.30B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

IDXX trades at a trailing price-to-earnings ratio of 37.18. That is 12.39% above the Diagnostics & Research median of 33.08. The forward P/E on file is 31.98. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.98. Measured against sales, the shares trade at 9.26 times revenue. On price-to-sales that is 85.63% above the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The trailing one-year price return is −16.40%. Measured over 10 years, that is +16.72% a year compounded. The reported beta is 1.54. Annualized volatility over the trailing 10 years is 33.01%.

Growth & Income

No dividend is on file for IDXX.

Across the complete calendar years on file, 2020 returned +91.43% and 2022 returned −38.04%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the price is −20.86%.

Peer Comparison

IDEXX Laboratories, Inc. (IDXX) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IDEXX Laboratories, Inc. IDXX $42.18B 37.2
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. IDEXX Laboratories, Inc. trades at a P/E of 37.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 WAT

Waters Corporation

$40.20B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Visit website →